Physician profile
Jiaxi Ding
NPI 1457648412
$12,956.18
in general payments reported to CMS, 2019-2025
17 companies · $7,139 in 2025
The $7,139 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.78 · 2020: $29.47 · 2021: $4,054 · 2022: $1,116 · 2023: $311 · 2024: $261 · 2025: $7,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Food and Beverage: $1,184 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Food and Beverage | $1,183.51 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $6,837.56 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $4,912.12 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $237.17 | 2022-2025 | Xen Glaucoma Treatment System |
| Alcon Vision LLC | $210.82 | 2022-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $150.70 | 2022-2025 | Tecnis Iol |
| Nova Eye, INC. | $127.35 | 2025 | |
| New World Medical,INC. | $90.14 | 2020-2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Allergan, INC. | $88.72 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $66.67 | 2020-2021 | |
| Oyster Point Pharma, INC. | $53.25 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $39.73 | 2022-2023 | Vyzulta |
| Glaukos Corporation | $39.65 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Rayner Intraocular Lenses Limited | $30.39 | 2022 | |
| Thea Pharma INC. | $19.99 | 2024 | Iyuzeh |
| Horizon Therapeutics Plc | $19.84 | 2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.53 | 2024 | Tepezza |
| Ivantis, INC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiaxi Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.